Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Lucinda Bateman, MD

BHC Medical Director, Provider

Education and Training

Personal Statement

After a decade of practicing general internal medicine (1989-1999), I was intimately aware of the need for advances in diagnosis and treatment guidelines for the generally misunderstood pain and fatigue illness spectrum including fibromyalgia (FM) and myalgic encephalomyeltitis/chronic fatigue syndrome (ME/CFS). In 2000, I changed my general clinical practice to a full-time Fatigue Consultation Clinic to learn more about diagnosis and management of such illnesses. Since then I have devoted my medical career exclusively to the diagnosis, management, research and education regarding FM and ME/CFS.  In 2002, I hired an experienced nurse to develop a clinical research program enabling us to contribute to FM and ME/CFS. We soon discovered that recruitment of subjects is one of the most challenging aspects of clinical research, and having a unique clinic devoted to these illnesses provided a great resource for well-defined research subjects.  Our patients regularly attend clinic visits and participate enthusiastically in research.   In the past few years I have served as principle investigator, clinical collaborator or medical advisor for more than 30 clinical trials directly related to FM or ME/CFS, including collaborations with NIH-funded basic and clinical researchers from the University of Utah, Columbia University, Nova Southeastern University, Harvard and Stanford, as well as the Centers for Disease Control and Prevention.

Positions and Honors

1991-2000:            Medical Associates of Salt Lake, Private Group Practice, General Internal Medicine

2000-15:                Fatigue Consultation Clinic, Medical Director  (Lucinda Bateman MD PC)

2002-15:          OFFER  (Organization for Fatigue and Fibromyalgia Education and Research).  Founder, Board of Directors, Executive Director [all volunteer].  This is a 501(c)3 nonprofit organization and OFFER was rebranded as the Bateman Horne Center in 2015—see below.

2003-09:          IACFS/ME (International Association of Chronic Fatigue Syndrome/ME) Board of Directors and Secretary. Lifetime member.  www.iacfsme.org  

2005-08:                CFIDS Association of America, Board of Directors  (now www.SolveCFS.org)

2006-10:          CFS Advisory Committee (CFSAC), Dept of Health and Human Services (see second stint 2017)

2002-16:          Adjunct Instructor, University of Utah, Family and Preventive Medicine

2005-14:          Adjunct Assistant Professor, University of Utah, Department of Internal Medicine

2010-PR:        Adjunct Assistant Professor, University of Utah, Department of Anesthesiology

2014-15:          Committee member, Institute of Medicine, Clinical Diagnostic Criteria for ME/CFS

www.nationalacademies.org/hmd/Activities/Disease/DiagnosisMyalgicEncephalomyelitisChronicFatigueSyndrome.aspx

2015-PR:         Bateman Horne Center of Excellence, Board of Directors, Medical Director, www.BatemanHorneCenter.org

2016:               IACFSME Award:  The Governor Rudy Perpich Award for distinguished service to ME/CFS

2017-18:          Chronic Fatigue Syndrome Advisory Committee (CFSAC), DHHS.  Chair of subcommittee for Provider Education. 

https://www.hhs.gov/ash/advisory-committees/cfsac/index.html  

2019-PR:       NANDS (National Advisory Neurological Disorders and Stroke Council) Working Group member.

                        https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Advisory-Council   

Contributions to Science

1. Pharmaceutical trials for FM. When 3 novel drugs for FM were in phase III clinical trials (2004-2013), we became one of the highest enrolling clinics in the country for Phase III clinical trials for both the FM adult and then the FM pediatric studies.  This was directly related to our large, willing, well defined clinical population under expert supervision.  These studies led to the first FDA approved drugs for an illness that had previously been marginalized and stereotyped. While pharmaceutical trials are not always respected at the same level, these FDA drug approvals created a major change in awareness, frequency of diagnosis and steps toward better treatment.  My primary role was as principal investigator implementing the protocols at BHC, not as a consultant to the pharmaceutical companies, but I also volunteered my time toward the following publications relevant to these studies.

• Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, Bhadra-Brown P, Clair A, Chew ML, Scavone J. Pediatr Rheumatol Online J. 2016 Jul 30;14(1):46. doi: 10.1186/s12969-016-0106-4. PubMed PMID: 27475753; PubMed Central PMCID: PMC4967327.

• Burden of illness in fibromyalgia patients with comorbid depression. Bateman L, Sarzi-Puttini P, Burbridge CL, Landen JW, Masters ET, Bhadra Brown P, Scavone JM, Emir B, Vissing RS, Clair AG, Pauer LR. n. Clin Exp Rheumatol. 2016 Mar-Apr;34(2 Suppl 96): S106-13. Epub 2016 Mar 10. PubMed PMID: 27057659.

• Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program. Arnold LM, Bateman L, Palmer RH, Lin Y. Pediatr Rheumatol Online J. 2015 Jun 26;13:27. doi: 10.1186/s12969-015-0025-9. PubMed PMID: 26112278; PubMed Central PMCID: PMC4480575.

• Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Bateman L, Palmer RH, Trugman JM, Lin Y. J Pain Res. 2013 Apr 26;6:311-8. doi: 10.2147/JPR.S43395. Print 2013. PubMed PMID: 23658494; PubMed Central PMCID: PMC3643187.

2. Clinical diagnosis and management of FM. As member of the FibroCollaborative in 2010 I joined a select group of expert scientists and clinicians to develop diagnosis and treatment guidance for FM. While not a lead author, I was a strong voice for the primary care clinical perspective in the collaborative process.

• Arnold LM, Clauw DJ, Dunegan LJ, Turk DC; FibroCollaborative. A framework for fibromyalgia management for primary care providers. Mayo Clin Proc. 2012 May;87(5):488-96. doi: 10.1016/j.mayocp.2012.02.010. Review. PubMed PMID: 22560527; PubMed Central PMCID: PMC3498162.

• Arnold LM, Clauw DJ, McCarberg BH; FibroCollaborative. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc. 2011 May;86(5):457-64. doi: 10.4065/mcp.2010.0738. Review. PubMed PMID: 21531887; PubMed Central PMCID: PMC3084648.

3. Clinical diagnosis and management of ME/CFS.  Broader awareness of FM came first, powered by drug development and FDA approval of 3 drugs for treating FM pain from 2006-2009.  ME/CFS awareness has moved more slowly, because the illness has no “medical home” and has not been embraced by academia.  The following are publications that reflect my active participation in projects developed to improve clinical diagnosis and management of ME/CFS.

• Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. Washington (DC): National Academies Press (US); 2015 Feb.  The National Academies Collection: Reports funded by National Institutes of Health. https://www.ncbi.nlm.nih.gov/pubmed/25695122  

• CFS/ME: A Primer for Clinical Practitioners. 2012 and 2014 Editions. Friedberg, F, Bateman L, Bested A, Davenport T, Friedman K, Gurwitt A, Jason L, Lapp C, Stevens S, Underhill RA, Vallings R. IACFS/ME Primer Writing Committee. Copyright ©2012 International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. https://www.ncbi.nlm.nih.gov/pubmed/25695122

• Myalgic encephalomyelitis: International Consensus Criteria. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisbik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S. J Intern Med. 2011 Oct;270(4):327-38.  (ME treatment primer also produced from this group) https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2796.2011.02428.x

4. Participation in Multi-Site Clinical Trials of ME/CFS. Small cohorts and inconsistent application of case definitions has plagued the science of ME/CFS for decades.  Because of this, larger well-defined clinical populations are urgently needed.  My most important multi-site clinical collaborations have been the Chronic Fatigue Initiative, the CDC Multi-Site study, and the NIH funded Collaborative Research Centers.  Several publications, informed by clinical experts, are now available, with more to come.  Data from the early multi-site studies also informed the IOM committee charged with developing new evidence-based clinical diagnostic criteria for ME/CFS in 2014-2015.

• Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study. Bateman L, Salima Darakjy, Nancy Klimas, Daniel Peterson, Susan M. Levine, Ali Allen, Shane A. Carlson, Elizabeth Balbin, Gunnar Gottschalk & Dana March. Fatigue: Biomedicine, Health & Behavior. 06 Dec 2014. 

• Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. N.G. Klimas, G. Ironson, A. Carter, E. Balbin, L. Bateman, D. Felsenstein, S. Levine, D. Peterson, K. Chiu, A. Allen, K. Cunningham, C.G. Gottschalk, M. Fletcher, M. Hornig, C. Canning & A.L. Komaroff. Fatigue: Biomedicine, Health & Behavior, Volume 3, Issue 2, April 2015 Pages: 75-96.  DOI: 10.1080/21641846.2015.1023652

• Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L, Peterson DL, Gottschalk GC, Schultz AF, Che X, Eddy ML, Komaroff AL, Lipkin WI.  Adv. 2015;1:e1400121. 27 Feb 2015.

• Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study. Unger ER, Lin JS, Tian H, Natelson BH, Lange G, Vu D, Blate M, Klimas NG, Balbin EG, Bateman L, Allen A, Lapp CW, Springs W, Kogelnik AM, Phan CC, Danver J, Podell RN, Fitzpatrick T, Peterson DL, Gottschalk CG, Rajeevan MS; MCAM Study Group. Am J Epidemiol. 2017 Mar 17:1-10. doi: 10.1093/aje/kwx029. [Epub ahead of print]. PMID: 28338983

5. Objective measurement of Post-Exertional Malaise (PEM) in ME/CFS. While attending the Pain Research Center didactic at the University of Utah, I encountered bench and clinical investigators clearly knowledgeable about the emerging science of central pain amplification and fibromyalgia.  It was through these associations that I began collaborations with Drs. Alan and Kathleen Light to investigate the exercise intolerance and post-exertional malaise that distinguishes ME/CFS from fibromyalgia.  With the combination of my clinical experience and their skilled scientific inquiry and experience, we were able to demonstrate, objectively, the physiological consequences of exercise in patients with ME/CFS.  I have also acted as clinical advisor to Snell et al. in studies using cardiopulmonary exercise testing to demonstrate PEM.

• Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. Light AR, White AT, Hughen RW, Light KC.  J Pain. 2009 Oct;10(10):1099-112. doi: 10.1016/j.jpain.2009.06.003. Epub 2009 Jul 31.  PMID: 19647494 [Acknowledgments to Dr. Lucinda Bateman for referral of patients and clinical advice]

• Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. Light AR, Bateman L, Jo D, Hughen RW, Vanhaitsma TA, White AT, Light KC.. J Intern Med. 2012 Jan;271(1):64-81. doi: 10.1111/j.1365-2796.2011.02405.x. Epub 2011 Jul 13. PubMed PMID: 21615807; PubMed Central PMCID: PMC3175315.

• Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome. White AT, Light AR, Hughen RW, Bateman L, Martins TB, Hill HR, Light KC. Psychophysiology. 2010 Jul 1;47(4):615-24. Epub 2010 Mar 4.  

• Postexertional malaise in women with chronic fatigue syndrome. VanNess JM1, Stevens SR, Bateman L, Stiles TL, Snell C. J Womens Health(Larchmt). 2010 Feb;19(2):239-44. doi:10.1089/jwh.2009.1507.

Additional Information: Research Support and/or Scholastic Performance

NIH funded Collaborative Research Centers for ME/CFS.  In 2017 the NIH awarded 3 Collaborative Research Center grants for a total of $30 million over 5 years.  Bateman Horne Center contracted work with 2 of these centers.  We are the clinical core for the grant to Dr. Derya Unutmaz at Jackson Laboratories. His team will examine immune, metabolomic and microbiome signatures in patients from BHC ill less than 4 years with ME/CFS compared with those ill greater than 10 years. (1U54 NS105539-01) The second CRC grant was awarded to Dr. Ian Lipkin at Columbia University, Center for Solutions for ME/CFS, and BHC is one of the clinical sites that will implement his project to use cutting-edge technology to conduct comprehensive genetic analyses, metabolomic studies and provocative studies (1U54 AI138370-01).

CMEs Authored and Presented

“Unraveling the Complexity of Chronic Pain and Fatigue, Parts 1, 2 and 3”.  University of Utah Chronic Care series.   May 13-15, 2020.  AMA Category 1 Credits. 

“Update on Chronic Fatigue Syndrome Part 1: Clinical Diagnostic Criteria for Chronic Fatigue Syndrome/CFS now called Myalgic Encephalomyelitis or ME/CFS”.  2019.  Michigan State Medical Society On Demand Webinar CME.

“Update on Chronic Fatigue Syndrome Part 2: Uniting Compassion, Attention and Innovation to treat ME/CFS”. 2019.  Michigan State Medical Society On-Demand Webinar CME.

“Diagnosing Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: The Experts Weigh In”.  Medscape Feb 2019.  CME / ABIM MOC / CE

“Fibromyalgia and ME/CFS: updates and management tips for clinicians.” Bateman Horne Center of Excellence.  April 27, 2018.   4 ACCME AMA PRA Cat 1 credits

“Objective Diagnosis of ME/CFS”.  Advancing an International Research Agenda to Address ME/CFS research Priorities: From Basic Research to Clinical Practice.  Montreal ME/CFS conference.  May 3-5, 2018.  2 CME credits in Canada

“ME/CFS in Pregnancy.” University of Utah, Project ECHO, Pregnancy Care.    August 10, 2018. 1.0 ACCME Category 1 CME credit

“Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.”  Med/Peds ECHO.  August 16, 2018.  1.0 ACCME Category 1 CME credit

“ME/CFS: the ‘bad’ fibromyalgia patients?” Delivered to University of Utah Pain Clinic faculty and staff.   1 CME credit. March 3, 2017.

 “Helpful Hints for Treating Fibromyalgia.” Delivered at Intermountain, Dixie Medical Center, SWR.  February 3, 2017,  1 ACCME, AMA PRA Cat 1 credit

“New clinical diagnostic criteria for Chronic Fatigue Syndrome, now known as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Delivered at Intermountain, Dixie Medical Center, SWR.  October 6, 2017,  1 ACCME, AMA PRA Cat 1 credit

“Sleep dysregulation in ME/CFS and FM.”  Delivered to University of Utah Sleep Lab faculty and staff.  October 27, 2017. 1 CME credit

 “Uniting Compassion, Attention and Innovation to treat FM and ME/CFS.” Delivered to University of Utah Pain Clinic faculty and staff.  November 17, 2017.  1 CME credit

“ME/CFS and fibromyalgia: updates and management tips for clinicians.” Bateman Horne Center of Excellence.  December 1, 2017.  4 ACCME AMA PRA Cat 1 credits

“Advances in Fibromyalgia and Chronic Fatigue Syndrome, or SEID, Systemic Exertion Intolerance Disease.”  (1.5 hour)  Utah Physician Assistant program curriculum (10/14/16)

“Beyond Chronic Fatigue Syndrome and Myalgic Encephalomyelitis: Next Steps in Diagnosis and Treatment.”  (1.5 credit hour)  CME/CE lecture to FDA employees in Bethesda, MD.  February 2016.

“New Clinical Diagnostic Criteria for Chronic Fatigue Syndrome/CFS” (1 cr hr) WINO (Western Intermountain Neurological Organization.  Univ of Utah, Oct 2-3, 2015

“Helpful Hints for Treating Fibromyalgia.”  (1 cr hr)  Collegium Aesculapium Foundation CME conference.  (Oct 2, 2015)

“FM: Advances in Fibromyalgia”  May 2015. BYU HealthCenter medical staff.   (1 cr hr)

“ME/CFS and FM: Updates in diagnosis and treatment.” Utah Association for Justice CLE luncheon.  March 28, 2014.  1 cr hr.

“Advances in Fibromyalgia and Chronic Fatigue Syndrome”.   Lecture at the 23rd Annual Utah Academy of Physician Assistants John Allen Memorial CME Conference in Mesquite.  1 AMA PRA Cat 1 credit. April 20, 2013

“ME/CFS Diagnosis and Treatment: Signs of Progress and Reasons for Optimism” (1 hour CME lecture) .  Progress in Research, Diagnosis and Treatment: The New Jersey Chronic Fatigue Syndrome Association Conference.  Oct 22, 2012.   

“Diagnosis and Management of CFS”.  Centers for Disease Control and Prevention Website CME for HealthCare professionals.  6/27/12.  1.25 AMA PRA Category 1 Credits.

“Sleep Problems in CFS”.  CDC CME for HealthCare professionals. 6/11/12.  1 AMA PRA Category 1 Credit.

“Chronic Fatigue Syndrome:  The Challenges in Primary Care”. Medscape CME course on CFS funded by CDC.  0.5 AMA PRA Category 1 Credit. 

Publications

Milivojevic M, Che X, Bateman L, Cheng A, Garcia BA, Hornig M, Huber M, Klimas NG, Lee B, Lee H, Levine S, Montoya JG, Peterson DL, Komaroff AL, Lipkin WI. Plasma proteomic profiling suggests an association between antigen driven clonal B cell expansion and ME/CFS. PLoS One. 2020 Jul 21;15(7):e0236148. doi:.1371/journal.pone.0236148. eCollection 2020.

PMID: 32692761

Tokunaga K, Sung AP, Tang JJ, Guglielmo MJ, Smith-Gagen J, Bateman L, Redelman DD, Hudig D Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS.. Work. 2020 Jun 16. doi: 10.3233/WOR-203177. Online ahead of print.

PMID: 32568152

Lee J, Wall P, Kimler C, Bateman L, Vernon SD. Clinically accessible tools for documenting the impact of orthostatic intolerance on symptoms and function in ME/CFS.

Work. 2020 Jun 16. doi: 10.3233/WOR-203169. Online ahead of print.

PMID: 32568144

Friedman KJ, Bateman L, Bested A, Nahle Z. Front Pediatr Editorial: Advances in ME/CFS Research and Clinical Care.. 2019 Sep 18;7:370. doi: 10.3389/fped.2019.00370. eCollection 2019. PMID: 31620406 Free PMC article. No abstract available.

Valdez AR, Hancock EE, Adebayo S, Kiernicki DJ, Proskauer D, Attewell JR, Bateman L, DeMaria A Jr, Lapp CW, Rowe PC, Proskauer C. Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning. Front Pediatr. 2019 Jan 8;6:412. doi: 10.3389/fped.2018.00412. eCollection 2018.  PMID: 30671425

Nagy-Szakal D, Barupal DK, Lee B, Che X, Williams BL, Kahn EJR, Ukaigwe JE, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG, Peterson DL, Levin B, Hornig M, Fiehn O, Lipkin WI. Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics. Sci Rep. 2018 Jul 3;8(1):10056. doi: 10.1038/s41598-018-28477-9. PMID: 29968805

Montoya JG, Anderson JN, Adolphs DL, Bateman L, Klimas N, Levine SM, Garvert DW, Kaiser, JD.  KPAX002 as a treatment for Myalgic Encephalomyelitis (ME/CFS): a prospective, randomized trial. Int J Clin Exp Med 2018;11(3):2890-2900 

Sung AP, Tang JJ, Guglielmo MJ, Redelman D, Smith-Gagen J, Bateman L, Hudig D.

An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells. J Immunol Methods. 2018 Jan;452:63-72. doi: 10.1016/j.jim.2017.11.002. Epub 2017 Nov 4.  PMID: 29113954

Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG, Peterson DL, Ramanan D, Jain K, Eddy ML, Hornig M, Lipkin WI. Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome. 2017 Apr 26;5(1):44. doi: 10.1186/s40168-017-0261-y. PMID: 28441964

Unger ER, Lin JS, Tian H, Natelson BH, Lange G, Vu D, Blate M, Klimas NG, Balbin EG, Bateman L, Allen A, Lapp CW, Springs W, Kogelnik AM, Phan CC, Danver J, Podell RN, Fitzpatrick T, Peterson DL, Gottschalk CG, Rajeevan MS; MCAM Study Group.  Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study. Am J Epidemiol. 2017 Apr 15;185(8):617-626. doi: 10.1093/aje/kwx029.

PMID: 28338983

Nicole L. Baldwin, Kristy O. Murray, Melissa N. Garcia, Lucinda Bateman. Treatment of postural orthostatic tachycardia syndrome and management of myalgic encephalomyelitis/chronic fatigue syndrome following suspected West Nile virus infection.  Fatigue: Biomedicine, Health & Behavior, Volume 4, 2016 – Issue 4.  Published Online: 03 Nov 2016

Arnold LM, Schikler KN, Bateman L, Khan T, Pauer L, Bhadra-Brown P, Clair A, Chew ML, Scavone J; Pregabalin Adolescent Fibromyalgia Study Group.; Safety and efficacy of pregabalin in adolescents with fibromyalgia: a randomized, double-blind, placebo-controlled trial and a 6-month open-label extension study. Pediatr Rheumatol Online J. 2016 Jul 30;14(1):46. doi: 10.1186/s12969-016-0106-4. PMID:  27475753

Bateman L, Sarzi-Puttini P, Burbridge CL, Landen JW, Masters ET, Bhadra Brown P, Scavone JM, Emir B, Vissing RS, Clair AG, Pauer LR.  Burden of illness in fibromyalgia patients with comorbid depression.  Clin Exp Rheumatol. 2016 Mar-Apr;34(2 Suppl 96):S106-13. Epub 2016 Mar 10. PMID: 27057659

10. Arnold, L.Bateman, RH. Palmer and Y.Lin. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program. Pediatric Rheumatology 2015, 13:27 doi:10.1186/s12969-015-0025-9

N.G. Klimas, G. Ironson, A. Carter, E. Balbin, L. Bateman, D. Felsenstein, S. Levine, D. Peterson, K. Chiu, A. Allen, K. Cunningham, C.G. Gottschalk, M. Fletcher, M. Hornig, C. Canning & A.L. Komaroff.  Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome.  Fatigue: Biomedicine, Health & Behavior, Volume 3, Issue 2, April 2015 Pages: 75-96.  DOI: 10.1080/21641846.2015.1023652

Hornig M, Montoys JG, Klimas NG, Levine S, Felsenstein D, Bateman L, Peterson DL, Gottschalk GC, Schultz AF, Che X, Eddy ML, Komaroff AL, Lipkin WI.  Distinct plasma immune signatures in ME/CFS are present early in the course of illness.  Sci.Adv. 2015;1:e1400121. 27 Feb 2015.

AT  White, KC. Light,  L Bateman, RW Hughen, TA Vanhaitsma, AR Light.  “Effect of Pregabalin on Cardiovascular Responses to Exercise and Postexercise Pain and Fatigue in Fibromyalgia: A Randomized, Double-Blind, Crossover Pilot Study,” Pain Research and Treatment, vol. 2015, Article ID 136409, 10 pages, 2015. doi:10.1155/2015/136409.

Bateman L, Salima Darakjy, Nancy Klimas, Daniel Peterson, Susan M. Levine, Ali Allen, Shane A. Carlson, Elizabeth Balbin, Gunnar Gottschalk & Dana March. Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study. Fatigue: Biomedicine, Health & Behavior.  06 Dec 2014

Irlbeck MD, Vernon DS, McCleary KK, Bateman L, Klimas GN, Lapp WC, Peterson LD, Brown RJ, Remlinger SK, Wilfret AD, Gerondelis  P.  No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank.  BMC Research Notes. 2014, 7:461. DOI: 10.1186/1756-0500-7-461.  URL: https://www.biomedcentral.com/1756-0500/7/461

Light KC, Agarwal N, Iacob E, White AT, Kinney AY, VanHaitsma TA, Aizad H, Hughen RW, Bateman L, Light AR.Differing leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.  Psychoneuroendocrinology. 2013 Dec;38(12):2983-95. doi: 10.1016/j.psyneuen.2013.08.008. Epub 2013 Sep 6.

Bateman L, Spotila J.  Article on CFS does not reflect current best treatment practices.  Am Fam Physician. 2013 Apr 1;87(7):Online. No abstract available.

Bateman L, Palmer RH, Trugman JM, Lin Y.  Results of switching to milnacipran in fibromyalgia patients with an inadequate response to duloxetine: a phase IV pilot study. Journal of Pain Research. April 2013 Volume 2013:6 Pages 311 – 318

Strayer DR, Carter WA, Stouch BC, Stevens SR, Bateman L, Cimoch PJ, Lapp CW, Peterson DL A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.  Chronic Fatigue Syndrome AMP-516 Study Group, Mitchell WM. PLoS One. 2012;7(3):e31334.

Aslakson E, Szekely S, Vernon SD, Bateman L, Baumbach J, Setty Y. Live sequence charts to model medical information. Theor Biol Med Model. 2012 Jun 15;9(1):22.

Light AR, Bateman L, Jo D, Hughen RW, Vanhaitsma TA, White AT, Light KC. Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. J Intern Med. 2012 Jan;271(1):64-81.

Friedberg, F, Bateman L, Bested A, Davenport T, Friedman K, Gurwitt A, Jason L, Lapp C, Stevens S, Underhill RA, Vallings R. CFS/ME: A Primer for Clinical Practitioners. 2012 Edition. IACFS/ME Primer Writing Committee. Copyright ©2012 International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis

Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisbik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S. Myalgic encephalomyelitis: International Consensus Criteria.  J Intern Med. 2011 Oct;270(4):327-38.  (ME/CFS treatment primer also produced from this group)

Shin CH, Bateman L, Schlaberg R, Bunker AM, Leonard CJ, Hughen RW, Light AR, Light KC, Singh IR. Absence of XMRV retrovirus and other murine leukemia virus-related viruses in patients with chronic fatigue syndrome. J Virol. 2011 Jul;85(14):7195-202. Epub 2011 May 4.   

Albright F, Light K, Light A, Bateman L, Cannon-Albright LA. Evidence for a heritable predisposition to Chronic Fatigue Syndrome. BMC Neurol. 2011 May 27;11:62.  

White AT, Light AR, Hughen RW, Bateman L, Martins TB, Hill HR, Light KC. Severity of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue syndrome.  Psychophysiology. 2010 Jul 1;47(4):615-24. Epub 2010 Mar 4.  

VanNess JM, Stevens SR, Bateman L, Stiles TL, Snell CR. Postexertional malaise in women with chronic fatigue syndrome. J Womens Health (Larchmt). 2010 Feb;19(2):239-44.  

Van Ness M, Snell CR, Stevens SR, Bateman L, Keller B. Using Serial Cardiopulmonary Exercise Tests to Support a Diagnosis of Chronic Fatigue Syndrome. Medicine & Science in Sports & Exercise, 2006, 38 (5), S85.

Snell CR, Mark Van Ness M, Stevens SR, Bateman L, Betsy Keller B. Intravenous Saline Administration Improves Physical Functioning in a Patient with Chronic Fatigue Syndrome. Medicine & Science in Sports & Exercise, 2006, 38 (5), S35.  

Other Research/Publications

Arnold LM, Clauw DJ, Dunegan LJ, Turk DC; FibroCollaborative. A framework for fibromyalgia management for primary care providers. Mayo Clin Proc. 2012 May;87(5):488-96

Arnold LM, Clauw DJ, McCarberg BH; FibroCollaborative [Bateman part of collaborative]. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc. 2011 May;86(5):457-64. Review.   

Russell IJ, Holman AJ, Swick TJ, Alvarez-Horine S, Wang YG, Guinta D; Sodium Oxybate 06-008 FM Study Group [Bateman part of FM study group]. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study. Pain. 2011 May;152(5):1007-17. Epub 2011 Mar 11.   

Bateman L.  Treatment of ME/CFS and FMS.  Oral presentation at the NIH State of the Knowledge Conference, Bethesda MD.  April 6, 2011.

Bateman L.  CFS and the Exercise Conundrum.  Fall Newsletter and website, IACFS/ME.  2008.  https://www.iacfsme.org/CFSandExercise/tabid/103/Default.aspx          

Bateman L. Cause and Cure Pending: Treat the Syndrome Subsets of Chronic Fatigue Syndrome and Fibromyalgia. Chronic Fatigue and Fibromyalgia Forum. The Official Publication of the AACFS.  (AACFS Quarterly Newsletter), 2003.

Bateman L. Chronic Fatigue Syndrome: A handbook for Primary Care Providers published by Easter Seals Utah, 1998.